Palisade Bio
PALI
8 hedge funds and large institutions have $29.8K invested in Palisade Bio in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.53% less ownership
Funds ownership: 0.54% → 0.01% (-0.53%)
27% less funds holding
Funds holding: 11 → 8 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
95% less capital invested
Capital invested by funds: $648K → $29.8K (-$618K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.81K |
| 2 |
Morgan Stanley
New York
|
+$2.39K |
| 3 |
OCM
Orion Capital Management
Coronado,
California
|
+$704 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$246 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$208K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$137K |
| 3 |
VF
Virtu Financial
New York
|
-$106K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$102K |
| 5 |
Two Sigma Investments
New York
|
-$54.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $11.4K | +$2.39K | +68 | +46% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $9K | +$5.81K | +165 | New |
|
3
UBS Group
Zurich,
Switzerland
| $4.72K | -$6.51K | -185 | -68% |
|
4
JP Morgan Chase
New York
| $2K | -$1.13K | -32 | -43% |
|
5
Wells Fargo
San Francisco,
California
| $1.18K | – | – | – |
|
|
OCM
6
Orion Capital Management
Coronado,
California
| $1.05K | +$704 | +20 | New |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $426 | +$246 | +7 | +700% |
|
8
BlackRock
New York
| $28 | – | – | – |
|
9
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $4 | – | – | – |
|
|
CH
10
CVI Holdings
Wilmington,
Delaware
| – | -$208K | -2,667 | Closed |
|
|
WAM
11
Warberg Asset Management
Winnetka,
Illinois
| – | -$137K | -1,754 | Closed |
|
|
VF
12
Virtu Financial
New York
| – | -$106K | -1,364 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$102K | -1,313 | Closed |
|
|
14
Two Sigma Investments
New York
| – | -$54.1K | -693 | Closed |
|
PALI Hedge Fund Activity: Q1 2023 in Review
8 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2023, worth a combined $29.8K — down 95% from $648K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PALI and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $5.81K. The largest seller was CVI Holdings, exiting entirely with an estimated $208K sold.
- 8 institutional investors held Palisade Bio (PALI) as of Q1 2023, down from 11 in Q4 2022.
- Funds reported $29.8K of Palisade Bio stock for Q1 2023, down 95% quarter-over-quarter.
- 2 funds opened new Palisade Bio positions in Q1 2023 and 5 closed out, a net change of -3 holders.
- The largest Palisade Bio buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $5.81K added.
- The largest Palisade Bio seller in Q1 2023 was CVI Holdings, an estimated $208K sold.
Based on aggregated 13F filings for Q1 2023.